Related content

CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy

By Hartwig Werner   Strobel Oliver   Hinz Ulf   Fritz Stefan   Hackert Thilo   Roth Constanze   Büchler Markus   Werner Jens  

Annals of Surgical Oncology, Vol. 20, Iss. 7, 2013-07 ,pp. : 2188-2196

Springer Publishing Company

Access to resources Recommend Favorite

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

By Katz Matthew  

Annals of Surgical Oncology, Vol. 17, Iss. 7, 2010-07 ,pp. : 1794-1801

Springer Publishing Company

Access to resources Recommend Favorite

Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

By Maithel Shishir  

Annals of Surgical Oncology, Vol. 15, Iss. 12, 2008-12 ,pp. : 3512-3520

Springer Publishing Company

Access to resources Recommend Favorite

Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

By Varadhachary Gauri   Tamm Eric   Abbruzzese James   Xiong Henry   Crane Christopher   Wang Huamin   Lee Jeffrey   Pisters Peter   Evans Douglas   Wolff Robert  

Annals of Surgical Oncology, Vol. 13, Iss. 8, 2006-08 ,pp. : 1035-1046

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer

By Kondo Naru  

Annals of Surgical Oncology, Vol. 17, Iss. 9, 2010-09 ,pp. : 2321-2329

Springer Publishing Company

Access to resources Recommend Favorite